Drugs / TQB3117
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06415903 | Jun 2024 → Jun 2025 overdue | cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06415903 ↗ |
| Action | Inhibit | “TQB3117 is a protein inhibitor.” NCT06415903 ↗ |
| Route | Oral | “Oral administration on fast condition” NCT06415903 ↗ |